Remove 2014 Remove Leads Remove Side effects
article thumbnail

Cala® Launches The Cala kIQ™ System, Offering Meaningful Tremor Relief for Patients With Essential Tremor and Now Parkinson’s Disease

Legacy MEDSearch

The Cala kIQ System with TAPS therapy offers a non-invasive, non-pharmacologic solution with minimal side effects. Founded in 2014, the company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. Novo Nordisk is another company leading the charge in this field. In the US, obesity care is estimated at to cost $147 billion in healthcare spending annually.

Medical 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. Novo Nordisk is another company leading the charge in this field. In the US, obesity care is estimated at to cost $147 billion in healthcare spending annually.

Medical 98
article thumbnail

Novel oral chemotherapeutic holds potential for stomach cancer patients

European Pharmaceutical Review

There is an urgent need for more effective chemotherapy treatments with less severe toxicity and side effects. Irinotecan – also known by the brand name Campto/Camptosar ® (Pfizer Ltd.) – has proven to be an effective chemotherapy agent against several types of gastrointestinal cancer. Camptosar prescribing information.

Patients 104
article thumbnail

Tributes as former NICE, MHRA chair Sir Mike Rawlins dies

pharmaphorum

A pharmacologist by training, Rawlins was the founding chairman of health technology assessment (HTA) agency NICE , leading the organisation from its inception in 1999 until 2013, and hired Sir Andrew Dillon to become the organisation’s founding chief executive.

article thumbnail

NICE says statins should be used more widely in NHS

pharmaphorum

” NICE warned that potential recipients of statins need to be carefully assessed as the drugs have potential side effects such as myopathy and muscle pains, and stressed that they should not be viewed as a substitute to lifestyle changes such as a healthier diet and more exercise.

article thumbnail

Nanotechnology: A Massive Impact at the Molecular Level

Celeritas

They only partially impact the target areas and have damaging side effects in adjacent regions. Gold nanowires further positively impact key organ transplant functions – synapse formation and stem cell differentiation – all without using growth factors, which cause negative side effects. 2014; 2 (11):1584–1593. [18]